Europe News
Filter News
Found 75,778 articles
-
Middle East and Africa pharma economy to reach US$38.8bn by 2021
8/15/2018
CPhI MEA (Middle East and Africa) launches next month as favourable market conditions are driving increased growth across the Middle East and North Africa (MENA) pharma market – ageing and gentrifying populations, increased healthcare spending, and a modernising supply chain are transforming prospects in the region.
-
In September 2016, the U.S. FDA approved Sarepta Therapeutics’ eteplirsen, now marketed as Exondys 51, for Duchenne muscular dystrophy (DMD). And now, two years later, the European Medicines Agency (EMA) has rejected Sarepta’s application for Exondys 51.
-
September 21 Research Roundup: Zombie Cells, Pancreatic Cancer, Household Cleaners and Obesity, a...
9/21/2018
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them. -
Almirall acquires Allergan U.S. medical dermatology portfolio*
9/21/2018
lmirall, S.A.(ALM) announced today the finalization of their acquisition of products from Allergan's Medical Dermatology unit in the United States: Aczone® (dapsone), Tazorac® (tazarotene), Azelex® (azelaic acid) and Cordran® Tape (flurandrenolide).
-
Diabetic Nephropathy - A Drug Pipeline Analysis Report by Technavio
9/21/2018
Technavio has announced their latest drug pipeline analysis report on diabetic nephropathy. The report includes a comprehensive research on the pipeline molecules under investigation by the pharmaceutical companies within the defined data collection period for the treatment of diabetic nephropathy.
-
Trelegy Ellipta Receives Positive CHMP Opinion Supporting Expanded COPD Indication in Europe
9/21/2018
GlaxoSmithKline plc and Innoviva, Inc. announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion today supporting the use of Trelegy Ellipta
-
CHMP Recommends Approval of Buvidal® (CAM2038) for the Treatment of Opioid Dependence
9/21/2018
On approval, Buvidal® would be the first long-acting medicine for treatment of opioid dependence in the EU
-
Medtronic To Acquire Mazor Robotics
9/21/2018
Acquisition to Accelerate Medtronic's Strategy to Transform Spinal Procedures and Improve Outcomes Through Fully-Integrated Surgical Solutions
-
Ipsen Receives Positive CHMP Opinion for Cabometyx® (Cabozantinib) for the Second-line Treatment of Patients with Hepatocellular Carcinoma (HCC)
9/21/2018
Ipsen announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), provided a positive opinion for Cabometyx® (cabozantinib) as a monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults
-
Johnson & Johnson Vision Showcases Latest Clinical Data and Eye Care Solutions at the ESCRS 2018 Annual Meeting
9/21/2018
Latest clinical data builds on the wealth of evidence supporting the safety, efficacy and overall benefits of TECNIS Symfony® IOLs for cataract patients
-
LineaRx, a subsidiary of Applied DNA Sciences, has entered into a Joint Development Agreement with Takis SRL and Evvivax SLR. They will focus on developing anti-cancer vaccines.
-
First Patient Included into ISR's Phase IIa HIV Study
9/20/2018
As previously announced, ISR has a Phase IIa study of HIV-infected patients on anti-retroviral therapy (ART), where patients will be randomized to receive GnRH agonist (ISR048) in addition to ART, or ART alone. The first patient is now enrolled.
-
Advicenne Reports First-Half 2018 Results and Confirms Outlook for 2018
9/20/2018
Advicenne (Paris:ADVIC), a French company specializing in the development of therapeutic products for adults and children for the treatment of orphan renal and neurological diseases, today published its first-half financial results as of June 30, 2018 and confirms its operating outlook for 2018.
-
FCB Health Continues Global Expansion with New Frankfurt Office and Network Ambassadors Stationed in Amsterdam and Zurich
9/20/2018
Today, FCB Health Europe President Joerg Hempelmann announced the launch of FCB Health Frankfurt, along with Network ambassadors stationed in Amsterdam and Zurich.
-
Mylan and Fujifilm Kyowa Kirin Biologics Receive European Marketing Authorization for Hulio®, Biosimilar Adalimumab
9/20/2018
Mylan N.V. and Fujifilm Kyowa Kirin Biologics Co., Ltd. today announced that the European Commission (EC) has granted marketing authorization for Hulio® (Product Code: FKB327), a biosimilar to AbbVie's Humira® (adalimumab), for all indications.
-
Allergan Teams Up with Actor Scott Eastwood to Encourage Recognition of World Alzheimer's Day on September 21st
9/20/2018
The company and actor join forces to pay homage to those affected by Alzheimer's Disease
-
Axol Bioscience Opens US Office
9/20/2018
Axol, the rapidly growing specialist in human cell culture, is delighted to announce it has opened a new operational hub in the US.
-
VAXIMM Announces Regional Development and Commercialization Agreement with China Medical System Holdings
9/20/2018
CMS gains exclusive rights to current VAXIMM pipeline and option for future programs for China and other Asian countries, ex-Japan
-
Ingenza takes a stake in new spin-out company Amprologix
9/20/2018
Ingenza is pleased to announce that it has become a stakeholder in Amprologix, a spin-out company from the University of Plymouth.
-
Domainex appoints Dr Trevor Perrior as Chief Executive Officer
9/20/2018
Domainex Ltd is pleased to announce the appointment of Dr Trevor Perrior as Chief Executive Officer, effective from 1st October 2018.